High H pylori Eradication Rate with Rifabutin-Based Therapy
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.
Gastrointestinal Illnesses
COVID-19: Atypical GI Presentations
There are increasing data to support that many patients with COVID-19 can develop a myriad of gastrointestinal symptoms, which include mild diarrhea, nausea, vomiting and abdominal pain.
Revised Clostridioides difficile Practice Guidelines Had Significant Effect on Treatment Decisions
Publication of the revised clinical practice guidelines for Clostridioides difficile infection was followed by significant increases in use of oral vancomycin and fidaxomicin, and a significant decrease in use of oral metronidazole.
Changes to Normal Gastrointestinal Care During the COVID-19 Pandemic
The COVID-19 pandemic has caused physicians in the New York area to reevaluate how they care for patients with gastrointestinal (GI) diseases.
Microbiome-Based Therapy Looks Promising for Recurrent C Difficile Infection
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
Rotavirus Vaccination Reduces Children Hospitalizations and Deaths
With increasing numbers of countries implementing the use of the rotavirus vaccine, rotavirus and acute gastroenteritis hospitalizations and mortalities continue to show a sustained reduction.
C difficile Risk and Antibiotic Prescription Choices
Large variations in Clostridioides difficile infection risk resulting from antibiotic courses used for the same indications were identified.
Rotavirus Vaccination Program Linked to Sustained Reduction in Healthcare Resource Utilization
A rotavirus vaccination program led to significant and sustained reductions in both hospitalizations and emergency department visits across the US.
Decreasing Prevalence of H pylori and Associated Gastric and Duodenal Ulcers
The prevalence of H pylori infection continues to fall in the general population with only 16% of all gastric and 25% of all duodenal patients with ulcer harboring H pylori.
Bezlotoxumab Effective for Treating Recurrent Clostridioides difficile Infection
Bezlotoxumab, both alone and in combination with actoxumab, was effective in preventing recurrent Clostridioides difficile infection without increased risk for adverse events.
-
Loading...
-
Loading...
Next post in GI Illness
